General Information of Drug Combination (ID: DCKWNXK)

Drug Combination Name
Daunorubicin Azacitidine
Indication
Disease Entry Status REF
MDS Phase 2 [1]
Component Drugs Daunorubicin   DMQUSBT Azacitidine   DMTA5OE
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Daunorubicin
Disease Entry ICD 11 Status REF
Acute monocytic leukemia N.A. Approved [2]
Acute myelogenous leukaemia 2A41 Approved [2]
Acute myeloid leukaemia 2A60 Approved [3]
Kaposi sarcoma 2B57 Approved [4]
Leukemia N.A. Approved [2]
Solid tumour/cancer 2A00-2F9Z Phase 2 [5]
Daunorubicin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA replication (DNA repli) TTABD5E NOUNIPROTAC Modulator [14]
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Intercalator [15]
------------------------------------------------------------------------------------
Daunorubicin Interacts with 4 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [16]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [17]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [18]
Multidrug resistance-associated protein 6 (ABCC6) DT582KR MRP6_HUMAN Substrate [19]
------------------------------------------------------------------------------------
Daunorubicin Interacts with 6 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [20]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [20]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Metabolism [20]
NADPH-dependent carbonyl reductase 1 (CBR1) DE9JFMC CBR1_HUMAN Metabolism [21]
NADPH-dependent carbonyl reductase 3 (CBR3) DEIVKZ8 CBR3_HUMAN Metabolism [22]
NADPH-cytochrome P450 reductase (CPR) DE3N2FM NCPR_HUMAN Metabolism [23]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DME(s)
Daunorubicin Interacts with 111 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Carbonyl reductase 3 (CBR3) OT9G6SF0 CBR3_HUMAN Affects Response To Substance [22]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Increases Expression [24]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Decreases Expression [25]
Heterogeneous nuclear ribonucleoprotein D0 (HNRNPD) OT5UO1FA HNRPD_HUMAN Affects Response To Substance [26]
Inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) OT5VYOSM IKKE_HUMAN Affects Response To Substance [26]
SEC14-like protein 3 (SEC14L3) OTGQ8GWM S14L3_HUMAN Increases ADR [26]
Voltage-dependent T-type calcium channel subunit alpha-1G (CACNA1G) OTGKBRE4 CAC1G_HUMAN Decreases Expression [8]
Tyrosine-protein kinase JAK2 (JAK2) OTBIDOOR JAK2_HUMAN Decreases Expression [8]
Sodium channel subunit beta-2 (SCN2B) OTFAHJ38 SCN2B_HUMAN Decreases Expression [8]
LIM domain-binding protein 3 (LDB3) OTGQL1AM LDB3_HUMAN Decreases Expression [8]
Creatine kinase M-type (CKM) OTME0KO7 KCRM_HUMAN Decreases Expression [8]
Myosin-6 (MYH6) OT3YNCH1 MYH6_HUMAN Decreases Expression [8]
Troponin T, slow skeletal muscle (TNNT1) OT8PBOAR TNNT1_HUMAN Decreases Expression [8]
Receptor tyrosine-protein kinase erbB-3 (ERBB3) OTRSST0A ERBB3_HUMAN Decreases Expression [8]
Sarcoplasmic reticulum histidine-rich calcium-binding protein (HRC) OTDLEJ4T SRCH_HUMAN Decreases Expression [8]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Increases Expression [8]
Sodium/potassium-transporting ATPase subunit alpha-2 (ATP1A2) OTCF8OWW AT1A2_HUMAN Decreases Expression [8]
cAMP-dependent protein kinase catalytic subunit PRKX (PRKX) OTDAC6Z0 PRKX_HUMAN Increases Expression [8]
Myomesin-2 (MYOM2) OTD2UOXW MYOM2_HUMAN Decreases Expression [8]
Actin, alpha skeletal muscle (ACTA1) OTOVGLPG ACTS_HUMAN Decreases Expression [8]
Iroquois-class homeodomain protein IRX-4 (IRX4) OT0TV6WK IRX4_HUMAN Decreases Expression [8]
Ankyrin-2 (ANK2) OTWB4R1Y ANK2_HUMAN Decreases Expression [8]
Dual specificity protein phosphatase 4 (DUSP4) OT6WAO12 DUS4_HUMAN Increases Expression [8]
Sodium channel protein type 5 subunit alpha (SCN5A) OTGYZWR6 SCN5A_HUMAN Decreases Expression [8]
Protein phosphatase 1 regulatory subunit 3A (PPP1R3A) OTJL9VYP PPR3A_HUMAN Decreases Expression [8]
Caveolae-associated protein 4 (CAVIN4) OTB1DM2C CAVN4_HUMAN Decreases Expression [8]
Nebulin-related-anchoring protein (NRAP) OTO6H3YF NRAP_HUMAN Decreases Expression [8]
Ryanodine receptor 2 (RYR2) OT0PF19E RYR2_HUMAN Decreases Expression [8]
Histone-lysine N-methyltransferase PRDM16 (PRDM16) OT0BGA27 PRD16_HUMAN Decreases Expression [8]
Voltage-dependent calcium channel subunit alpha-2/delta-2 (CACNA2D2) OTFJXVQQ CA2D2_HUMAN Decreases Expression [8]
Atrial natriuretic peptide-converting enzyme (CORIN) OT4SK7DK CORIN_HUMAN Decreases Expression [8]
Agrin (AGRN) OTWJENAZ AGRIN_HUMAN Increases Expression [27]
Etoposide-induced protein 2.4 homolog (EI24) OTD4NOYS EI24_HUMAN Increases Expression [27]
Tax1-binding protein 3 (TAX1BP3) OTQ6IB4T TX1B3_HUMAN Increases Expression [27]
Protein Mdm4 (MDM4) OTU10BSF MDM4_HUMAN Decreases Expression [28]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Increases Expression [29]
Cytoplasmic protein NCK2 (NCK2) OTUYPF55 NCK2_HUMAN Decreases Expression [27]
Protein regulator of cytokinesis 1 (PRC1) OTHD0XS0 PRC1_HUMAN Decreases Expression [27]
Plasminogen activator inhibitor 1 (SERPINE1) OTT0MPQ3 PAI1_HUMAN Decreases Expression [30]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Increases Expression [28]
Interleukin-6 receptor subunit alpha (IL6R) OTCQL07Z IL6RA_HUMAN Decreases Expression [10]
Annexin A4 (ANXA4) OTUCRYXL ANXA4_HUMAN Increases Expression [27]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [31]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Expression [10]
C-C motif chemokine 4 (CCL4) OT6B8P25 CCL4_HUMAN Decreases Expression [10]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [10]
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) OTPWI88U CEAM1_HUMAN Increases Expression [27]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [32]
Natriuretic peptides B (NPPB) OTSN2IPY ANFB_HUMAN Increases Expression [33]
NADPH:adrenodoxin oxidoreductase, mitochondrial (FDXR) OTPDCK1F ADRO_HUMAN Increases Expression [27]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Phosphorylation [32]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Phosphorylation [32]
G1/S-specific cyclin-D3 (CCND3) OTNKPQ22 CCND3_HUMAN Increases Expression [28]
M-phase inducer phosphatase 1 (CDC25A) OTSLKKCO MPIP1_HUMAN Increases Expression [28]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [28]
Tumor necrosis factor ligand superfamily member 9 (TNFSF9) OTV9L89D TNFL9_HUMAN Increases Expression [27]
Cyclin-dependent kinase inhibitor 2A (CDKN2A) OTN0ZWAE CDN2A_HUMAN Affects Expression [28]
Cyclin-dependent kinase 4 inhibitor B (CDKN2B) OTAG24N1 CDN2B_HUMAN Increases Expression [28]
Dual specificity mitogen-activated protein kinase kinase 3 (MAP2K3) OTI2OREX MP2K3_HUMAN Increases Expression [27]
Dual specificity protein kinase CLK2 (CLK2) OT1CRSY2 CLK2_HUMAN Increases Expression [28]
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform (PPP2CA) OT83PT85 PP2AA_HUMAN Increases Expression [32]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Affects Expression [29]
Transcription factor Sp3 (SP3) OTYDQZ1T SP3_HUMAN Increases Expression [34]
CCAAT/enhancer-binding protein zeta (CEBPZ) OT11BATG CEBPZ_HUMAN Decreases Expression [27]
Serine-protein kinase ATM (ATM) OTQVOHLT ATM_HUMAN Increases Expression [28]
Retinoblastoma-binding protein 5 (RBBP5) OT12W2MK RBBP5_HUMAN Affects Expression [28]
Transcription factor E2F5 (E2F5) OT1XWING E2F5_HUMAN Increases Expression [28]
Cyclin-G2 (CCNG2) OTII38K2 CCNG2_HUMAN Increases Expression [35]
Quinone oxidoreductase PIG3 (TP53I3) OTSCM68G QORX_HUMAN Increases Expression [27]
EPM2A-interacting protein 1 (EPM2AIP1) OT21ALNF EPMIP_HUMAN Increases Expression [27]
E3 ubiquitin-protein ligase RBBP6 (RBBP6) OTTVG4HU RBBP6_HUMAN Increases Expression [28]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Decreases Activity [9]
Mitogen-activated protein kinase kinase kinase 5 (MAP3K5) OTQR6ENW M3K5_HUMAN Decreases Expression [27]
BRCA1-associated RING domain protein 1 (BARD1) OTTC0Z9Y BARD1_HUMAN Affects Expression [28]
Serine/threonine-protein kinase PLK3 (PLK3) OT19CT2Z PLK3_HUMAN Increases Expression [27]
Sphingomyelin phosphodiesterase 3 (SMPD3) OTHQBETH NSMA2_HUMAN Increases Expression [34]
F-box/WD repeat-containing protein 1A (BTRC) OT2EZDGR FBW1A_HUMAN Increases Expression [32]
Calcium-binding protein 39 (CAB39) OT2CL9ST CAB39_HUMAN Decreases Expression [27]
Integrin-linked kinase-associated serine/threonine phosphatase 2C (ILKAP) OT2A6FSA ILKAP_HUMAN Affects Response To Substance [12]
Kinesin-like protein KIF1A (KIF1A) OT3JVEGV KIF1A_HUMAN Affects Response To Substance [12]
Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1) OT5BZ1J9 P85A_HUMAN Affects Response To Substance [12]
Solute carrier family 28 member 3 (SLC28A3) OT5TLTYU S28A3_HUMAN Increases ADR [11]
Protein GAPT (GAPT) OT6C2WXX GAPT_HUMAN Affects Response To Substance [12]
Glypican-5 (GPC5) OT8NR7GC GPC5_HUMAN Affects Response To Substance [12]
Voltage-dependent L-type calcium channel subunit alpha-1S (CACNA1S) OT96MCM2 CAC1S_HUMAN Affects Response To Substance [12]
Ephexin-1 (NGEF) OT9QUXJ3 NGEF_HUMAN Affects Response To Substance [12]
Spliceosome-associated protein CWC27 homolog (CWC27) OTB0HBP1 CWC27_HUMAN Affects Response To Substance [12]
Cadherin-13 (CDH13) OTD2CYM5 CAD13_HUMAN Affects Response To Substance [12]
Sp110 nuclear body protein (SP110) OTFW6WH7 SP110_HUMAN Affects Response To Substance [12]
Leucine zipper protein 2 (LUZP2) OTGGOSPW LUZP2_HUMAN Affects Response To Substance [12]
Transgelin-3 (TAGLN3) OTJBP3VJ TAGL3_HUMAN Affects Response To Substance [12]
Inositol polyphosphate 4-phosphatase type II (INPP4B) OTLROA7G INP4B_HUMAN Affects Response To Substance [12]
Anoctamin-3 (ANO3) OTM34U6Q ANO3_HUMAN Affects Response To Substance [12]
RelA-associated inhibitor (PPP1R13L) OTNCPLWE IASPP_HUMAN Decreases Response To Substance [36]
Transmembrane 4 L6 family member 20 (TM4SF20) OTNXU9QW T4S20_HUMAN Affects Response To Substance [12]
Aldo-keto reductase family 1 member B10 (AKR1B10) OTOA4HTH AK1BA_HUMAN Decreases Response To Substance [37]
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN) OTOWDUNT PTEN_HUMAN Increases Response To Substance [38]
Ran-binding protein 17 (RANBP17) OTQEVTYH RBP17_HUMAN Affects Response To Substance [12]
NPC intracellular cholesterol transporter 1 (NPC1) OTRIPICX NPC1_HUMAN Increases Secretion [39]
Aldo-keto reductase family 1 member B1 (AKR1B1) OTRX72TH ALDR_HUMAN Increases Reduction [40]
COX assembly mitochondrial protein 2 homolog (CMC2) OTRYIO1J COXM2_HUMAN Affects Response To Substance [12]
Protein SPMIP2 (SPMIP2) OTSNYR9R SMIP2_HUMAN Affects Response To Substance [12]
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Decreases Response To Substance [41]
Slit homolog 3 protein (SLIT3) OTU8MKEU SLIT3_HUMAN Affects Response To Substance [12]
Microtubule-associated protein 1B (MAP1B) OTVXW089 MAP1B_HUMAN Affects Response To Substance [12]
Antigen peptide transporter 2 (TAP2) OTWSYFI7 TAP2_HUMAN Affects Response To Substance [26]
Citramalyl-CoA lyase, mitochondrial (CLYBL) OTXZLTST CLYBL_HUMAN Affects Response To Substance [12]
Limbic system-associated membrane protein (LSAMP) OTYXVQX2 LSAMP_HUMAN Affects Response To Substance [12]
C-Maf-inducing protein (CMIP) OTZN8Z4A CMIP_HUMAN Affects Response To Substance [12]
Aldo-keto reductase family 1 member A1 (AKR1A1) OTZT9NOW AK1A1_HUMAN Increases Reduction [42]
EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1) OTZVUOOB FBLN3_HUMAN Affects Response To Substance [43]
------------------------------------------------------------------------------------
⏷ Show the Full List of 111 DOT(s)
Indication(s) of Azacitidine
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [6]
Chronic myelomonocytic leukemia N.A. Approved [6]
Leukemia N.A. Approved [6]
Myelodysplastic syndrome 2A37 Approved [7]
Myeloproliferative neoplasm 2A20 Approved [6]
Plasma cell myeloma 2A83.1 Approved [6]
Azacitidine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA [cytosine-5]-methyltransferase (DNMT) TTHVCUP NOUNIPROTAC Inhibitor [48]
------------------------------------------------------------------------------------
Azacitidine Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytidine aminohydrolase (CDA) DEKEDRC CDD_HUMAN Metabolism [49]
Cytidine deaminase (cdd) DEYILK4 E0TLJ6_MYCHH Metabolism [50]
------------------------------------------------------------------------------------
Azacitidine Interacts with 202 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Affects Expression [51]
Tectonin beta-propeller repeat-containing protein 2 (TECPR2) OT1UFECZ TCPR2_HUMAN Increases Expression [44]
TBC1 domain family member 4 (TBC1D4) OTK66C40 TBCD4_HUMAN Decreases Expression [44]
Multiple epidermal growth factor-like domains protein 6 (MEGF6) OTEUYTP1 MEGF6_HUMAN Decreases Expression [44]
Protein S100-A9 (S100A9) OTOARHCS S10A9_HUMAN Increases Expression [44]
Receptor-type tyrosine-protein phosphatase C (PTPRC) OT6KOR77 PTPRC_HUMAN Increases Expression [44]
Heat shock 70 kDa protein 6 (HSPA6) OTH4S7WB HSP76_HUMAN Increases Expression [44]
Gamma-aminobutyric acid receptor subunit beta-1 (GABRB1) OT4L2SSB GBRB1_HUMAN Increases Expression [44]
Transcription factor E3 (TFE3) OTM99ZWH TFE3_HUMAN Increases Expression [44]
Protein S100-P (S100P) OTJCXNJG S100P_HUMAN Increases Expression [44]
Protein PML (PML) OT6SM2GD PML_HUMAN Increases Expression [44]
DNA-binding protein inhibitor ID-1 (ID1) OTKGNZN5 ID1_HUMAN Increases Expression [44]
Cyclin-dependent kinase 4 inhibitor B (CDKN2B) OTAG24N1 CDN2B_HUMAN Decreases Methylation [44]
LIM and senescent cell antigen-like-containing domain protein 1 (LIMS1) OT729S0T LIMS1_HUMAN Increases Expression [44]
E3 SUMO-protein ligase RanBP2 (RANBP2) OTFG5CVF RBP2_HUMAN Increases Expression [44]
Cyclin-dependent kinase inhibitor 1C (CDKN1C) OTASTJ3Q CDN1C_HUMAN Increases Expression [44]
Ras-related protein Rab-13 (RAB13) OTIQ484I RAB13_HUMAN Decreases Methylation [44]
Claudin-10 (CLDN10) OT2CVAKY CLD10_HUMAN Decreases Expression [44]
Sushi repeat-containing protein SRPX (SRPX) OT5B9LXS SRPX_HUMAN Decreases Expression [44]
DNA-binding protein inhibitor ID-3 (ID3) OTUULW5Z ID3_HUMAN Increases Expression [44]
Collagen alpha-1(XIV) chain (COL14A1) OTLNJ13O COEA1_HUMAN Increases Expression [44]
Equilibrative nucleoside transporter 2 (SLC29A2) OTUAOB8T S29A2_HUMAN Decreases Expression [44]
Cytohesin-1 (CYTH1) OTYH9NRJ CYH1_HUMAN Increases Expression [44]
DNA dC->dU-editing enzyme APOBEC-3F (APOBEC3F) OT750IJM ABC3F_HUMAN Increases Expression [44]
Angiogenic factor with G patch and FHA domains 1 (AGGF1) OTA7U2T8 AGGF1_HUMAN Increases Expression [44]
E3 ubiquitin-protein ligase Praja-1 (PJA1) OTFKTMEI PJA1_HUMAN Increases Expression [44]
Tetraspanin-32 (TSPAN32) OTSXW7EW TSN32_HUMAN Decreases Expression [44]
Tribbles homolog 1 (TRIB1) OTPEO17G TRIB1_HUMAN Decreases Expression [44]
Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LITAF) OTT5JX1F LITAF_HUMAN Decreases Expression [44]
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha (PIP5K1A) OTVTB5R5 PI51A_HUMAN Decreases Expression [44]
Centromere protein O (CENPO) OTXAH83Y CENPO_HUMAN Increases Expression [44]
Iron-sulfur cluster assembly 1 homolog, mitochondrial (ISCA1) OTU230MC ISCA1_HUMAN Increases Expression [44]
E3 ubiquitin-protein ligase TRIM8 (TRIM8) OTS6JFR0 TRIM8_HUMAN Increases Expression [44]
Uncharacterized protein C6orf62 (C6ORF62) OTGK4G35 CF062_HUMAN Increases Expression [44]
Metal transporter CNNM2 (CNNM2) OTZHO8WU CNNM2_HUMAN Decreases Expression [44]
DNA dC->dU-editing enzyme APOBEC-3G (APOBEC3G) OT410VP5 ABC3G_HUMAN Increases Expression [44]
NTF2-related export protein 2 (NXT2) OTK82YVT NXT2_HUMAN Increases Expression [44]
THUMP domain-containing protein 1 (THUMPD1) OTKU8KWH THUM1_HUMAN Increases Expression [44]
Protein FAM8A1 (FAM8A1) OT1QVTGS FA8A1_HUMAN Increases Expression [44]
Type 2 lactosamine alpha-2,3-sialyltransferase (ST3GAL6) OTB17Q43 SIA10_HUMAN Increases Expression [44]
Methionine-R-sulfoxide reductase B2, mitochondrial (MSRB2) OTURGRA8 MSRB2_HUMAN Increases Expression [44]
Mitotic spindle assembly checkpoint protein MAD1 (MAD1L1) OTJCX8K9 MD1L1_HUMAN Decreases Expression [44]
Signal-regulatory protein beta-1 (SIRPB1) OTGHALWJ SIRB1_HUMAN Decreases Expression [45]
Syntenin-1 (SDCBP) OTS3NCC5 SDCB1_HUMAN Decreases Expression [45]
Complexin-1 (CPLX1) OT7UIGTP CPLX1_HUMAN Increases Expression [45]
Nephrocystin-1 (NPHP1) OTZHCFFQ NPHP1_HUMAN Increases Expression [45]
Phosphatase and actin regulator 2 (PHACTR2) OTWMX2A8 PHAR2_HUMAN Increases Expression [45]
Nuclear factor of activated T-cells, cytoplasmic 1 (NFATC1) OT4TMERS NFAC1_HUMAN Increases Expression [45]
Metalloproteinase inhibitor 1 (TIMP1) OTOXC51H TIMP1_HUMAN Increases Expression [45]
Cystatin-C (CST3) OTNZ6AO4 CYTC_HUMAN Increases Expression [45]
Cystatin-S (CST4) OTXXM8EH CYTS_HUMAN Increases Expression [45]
Interstitial collagenase (MMP1) OTI4I2V1 MMP1_HUMAN Increases Expression [45]
Keratin, type II cytoskeletal 8 (KRT8) OTTM4X11 K2C8_HUMAN Increases Expression [45]
Neurofilament light polypeptide (NEFL) OTQESJV4 NFL_HUMAN Increases Expression [45]
Protein disulfide-isomerase (P4HB) OTTYNYPF PDIA1_HUMAN Increases Expression [45]
Profilin-1 (PFN1) OTHTGA1H PROF1_HUMAN Increases Expression [45]
Tropomyosin beta chain (TPM2) OTA1L0P8 TPM2_HUMAN Increases Expression [45]
Small ribosomal subunit protein uS2 (RPSA) OTJZHEGT RSSA_HUMAN Decreases Expression [45]
Glycodelin (PAEP) OTQA0NV4 PAEP_HUMAN Decreases Expression [45]
E3 SUMO-protein ligase EGR2 (EGR2) OTAVQ78J EGR2_HUMAN Increases Expression [45]
Pregnancy-specific beta-1-glycoprotein 1 (PSG1) OT1U4ZZW PSG1_HUMAN Increases Expression [45]
Collagen alpha-3(VI) chain (COL6A3) OTAS6R6I CO6A3_HUMAN Decreases Expression [45]
Parathyroid hormone-related protein (PTHLH) OTI1JF13 PTHR_HUMAN Decreases Expression [45]
Plastin-3 (PLS3) OTYBM4PK PLST_HUMAN Decreases Expression [45]
Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial (MTHFD2) OT1LQSGX MTDC_HUMAN Decreases Expression [45]
Desmin (DES) OTI09KBW DESM_HUMAN Increases Expression [45]
5'-nucleotidase (NT5E) OT7J5LT6 5NTD_HUMAN Increases Expression [45]
Fibroblast growth factor 7 (FGF7) OTGK6ANL FGF7_HUMAN Decreases Expression [45]
Insulin-like growth factor-binding protein 4 (IGFBP4) OT2HZRBD IBP4_HUMAN Increases Expression [45]
Transcription elongation factor A protein 1 (TCEA1) OTBFO594 TCEA1_HUMAN Decreases Expression [45]
V-type proton ATPase 16 kDa proteolipid subunit c (ATP6V0C) OTKPL09B VATL_HUMAN Increases Expression [45]
Protein ITPRID2 (ITPRID2) OTO3JDX5 ITPI2_HUMAN Increases Expression [45]
Interleukin-12 subunit beta (IL12B) OT0JF8A3 IL12B_HUMAN Increases Expression [45]
Neurotensin/neuromedin N (NTS) OTPGDNQS NEUT_HUMAN Decreases Expression [45]
Guanylate-binding protein 2 (GBP2) OTVU4G07 GBP2_HUMAN Decreases Expression [45]
MHC class II transactivator (CIITA) OTRJNZFO C2TA_HUMAN Increases Expression [45]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [45]
Exosome RNA helicase MTR4 (MTREX) OTSQY30V MTREX_HUMAN Increases Expression [45]
Alpha-S1-casein (CSN1S1) OTXOW6XJ CASA1_HUMAN Increases Expression [45]
Nuclear receptor-interacting protein 1 (NRIP1) OTIZOJQV NRIP1_HUMAN Decreases Expression [45]
Homeobox protein Hox-A1 (HOXA1) OTMSOJ7D HXA1_HUMAN Increases Expression [45]
Ephrin-A3 (EFNA3) OTJGOUMZ EFNA3_HUMAN Increases Expression [45]
GPI-linked NAD(P)(+)--arginine ADP-ribosyltransferase 1 (ART1) OT7FBG5W NAR1_HUMAN Increases Expression [45]
Branched-chain-amino-acid aminotransferase, cytosolic (BCAT1) OTYHXLWZ BCAT1_HUMAN Decreases Expression [45]
Microfibrillar-associated protein 2 (MFAP2) OTMHVBTV MFAP2_HUMAN Decreases Expression [45]
Laminin subunit beta-2 (LAMB2) OT71OI2Y LAMB2_HUMAN Increases Expression [45]
NHP2-like protein 1 (SNU13) OTH56TIH NH2L1_HUMAN Increases Expression [45]
Homeobox protein DLX-6 (DLX6) OT0FIJHY DLX6_HUMAN Increases Expression [45]
Elongation factor 1-alpha 1 (EEF1A1) OT00THXS EF1A1_HUMAN Decreases Expression [45]
Cytochrome c oxidase subunit 6A2, mitochondrial (COX6A2) OTQR5SXD CX6A2_HUMAN Increases Expression [45]
cAMP-responsive element modulator (CREM) OTJIJ5AL CREM_HUMAN Decreases Expression [45]
Caldesmon (CALD1) OTNJKJ6Q CALD1_HUMAN Increases Expression [45]
ATP-dependent RNA helicase A (DHX9) OT5AAOQI DHX9_HUMAN Decreases Expression [45]
Serine/threonine-protein kinase PAK 1 (PAK1) OT17LZNZ PAK1_HUMAN Increases Expression [45]
Dual specificity mitogen-activated protein kinase kinase 5 (MAP2K5) OT6T408U MP2K5_HUMAN Decreases Expression [45]
Chitotriosidase-1 (CHIT1) OTPQR0A6 CHIT1_HUMAN Increases Expression [45]
Ras and Rab interactor 1 (RIN1) OTPBROUD RIN1_HUMAN Increases Expression [45]
Keratin, type I cuticular Ha2 (KRT32) OTZCGZYT K1H2_HUMAN Increases Expression [45]
Ras GTPase-activating protein 3 (RASA3) OT9C54MN RASA3_HUMAN Increases Expression [45]
Mediator of DNA damage checkpoint protein 1 (MDC1) OTEUQH4J MDC1_HUMAN Increases Expression [45]
Mortality factor 4-like protein 2 (MORF4L2) OT8OI3EC MO4L2_HUMAN Decreases Expression [45]
kinase isozyme 1, mitochondrial (PDK1) OTMABK9Z PDK1_HUMAN Increases Expression [45]
Serine/threonine-protein kinase 38 (STK38) OTKMYCYR STK38_HUMAN Decreases Expression [45]
Serine/threonine-protein phosphatase 2A activator (PTPA) OTRGFOI7 PTPA_HUMAN Increases Expression [45]
Reticulocalbin-1 (RCN1) OT3JBGAG RCN1_HUMAN Decreases Expression [45]
Olfactory receptor 8B8 (OR8B8) OTCISNYV OR8B8_HUMAN Increases Expression [45]
Serine/arginine-rich splicing factor 7 (SRSF7) OTRS4W4S SRSF7_HUMAN Decreases Expression [45]
Guanylate kinase (GUK1) OTLI0HRU KGUA_HUMAN Increases Expression [45]
Filamin A-interacting protein 1-like (FILIP1L) OTPY8IMS FIL1L_HUMAN Decreases Expression [45]
Nucleolar MIF4G domain-containing protein 1 (NOM1) OTWZSJJC NOM1_HUMAN Decreases Expression [45]
Opioid growth factor receptor-like protein 1 (OGFRL1) OT6QGBYE OGRL1_HUMAN Increases Expression [45]
Serine/threonine-protein kinase MRCK alpha (CDC42BPA) OTCPFOSA MRCKA_HUMAN Decreases Expression [45]
Extracellular sulfatase Sulf-1 (SULF1) OTJCNCO0 SULF1_HUMAN Decreases Expression [45]
N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase (GCNT2) OTRUIMC4 GNT2A_HUMAN Decreases Expression [45]
Oxidation resistance protein 1 (OXR1) OTPIDMT3 OXR1_HUMAN Increases Expression [45]
Alpha-2,8-sialyltransferase 8B (ST8SIA2) OTRBBBD8 SIA8B_HUMAN Decreases Expression [45]
Type II iodothyronine deiodinase (DIO2) OTGPNSLH IOD2_HUMAN Decreases Expression [45]
G-patch domain and KOW motifs-containing protein (GPKOW) OTGS3H0M GPKOW_HUMAN Increases Expression [45]
Rho guanine nucleotide exchange factor 2 (ARHGEF2) OTBQTFRT ARHG2_HUMAN Decreases Expression [45]
Homogentisate 1,2-dioxygenase (HGD) OTTKLQOO HGD_HUMAN Increases Expression [45]
Secretory carrier-associated membrane protein 4 (SCAMP4) OTSCZTJ5 SCAM4_HUMAN Increases Expression [45]
Protein bicaudal D homolog 1 (BICD1) OT78IYPF BICD1_HUMAN Decreases Expression [45]
Ankyrin repeat and SOCS box protein 2 (ASB2) OTF9LV7L ASB2_HUMAN Increases Expression [45]
Eyes absent homolog 1 (EYA1) OTHU807A EYA1_HUMAN Decreases Expression [45]
Bcl-2-like protein 13 (BCL2L13) OT2VRFTM B2L13_HUMAN Increases Expression [45]
RNA helicase Mov10l1 (MOV10L1) OTP978LK M10L1_HUMAN Increases Expression [45]
Rac GTPase-activating protein 1 (RACGAP1) OTQE8IEH RGAP1_HUMAN Increases Expression [45]
Ras-related protein Rab-1B (RAB1B) OTAFCUAS RAB1B_HUMAN Increases Expression [45]
Semaphorin-6C (SEMA6C) OT1N59T5 SEM6C_HUMAN Increases Expression [45]
Sentrin-specific protease 3 (SENP3) OTFQDOMC SENP3_HUMAN Increases Expression [45]
Ribonuclease P protein subunit p21 (RPP21) OT53MDNE RPP21_HUMAN Increases Expression [45]
Protocadherin-18 (PCDH18) OTTLQWRN PCD18_HUMAN Decreases Expression [45]
Protein S100-A14 (S100A14) OTVFJJ91 S10AE_HUMAN Decreases Expression [45]
Tryptase gamma (TPSG1) OTDESHKT TRYG1_HUMAN Decreases Expression [45]
Rho GTPase-activating protein 35 (ARHGAP35) OTJ8POG0 RHG35_HUMAN Increases Expression [45]
Neuroligin-3 (NLGN3) OTKDEC1Q NLGN3_HUMAN Increases Expression [45]
Polycystin-2-like protein 1 (PKD2L1) OT1KJDAT PK2L1_HUMAN Increases Expression [45]
A disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS1) OTTLJH8W ATS1_HUMAN Decreases Expression [45]
Cytoplasmic phosphatidylinositol transfer protein 1 (PITPNC1) OT64TTGC PITC1_HUMAN Decreases Expression [45]
Transcription factor SOX-13 (SOX13) OTCIF6KC SOX13_HUMAN Decreases Expression [45]
Afadin- and alpha-actinin-binding protein (SSX2IP) OTEIZ7N1 ADIP_HUMAN Increases Expression [45]
Transmembrane emp24 domain-containing protein 3 (TMED3) OTNOPHHC TMED3_HUMAN Increases Expression [45]
Protocadherin beta-4 (PCDHB4) OTF665E0 PCDB4_HUMAN Decreases Expression [45]
Protocadherin beta-14 (PCDHB14) OTFZF1ST PCDBE_HUMAN Decreases Expression [45]
Adenylate kinase isoenzyme 5 (AK5) OTTGXLOT KAD5_HUMAN Increases Expression [45]
Albumin (ALB) OTVMM513 ALBU_HUMAN Increases Expression [52]
Tyrosine aminotransferase (TAT) OT2CJ91O ATTY_HUMAN Increases Expression [52]
CCAAT/enhancer-binding protein alpha (CEBPA) OTOM9OE4 CEBPA_HUMAN Increases Expression [52]
Hematopoietically-expressed homeobox protein HHEX (HHEX) OTLIUVYX HHEX_HUMAN Increases Expression [52]
Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-7 (GNG7) OTHS1L0E GBG7_HUMAN Affects Methylation [53]
Claudin-7 (CLDN7) OTNE0XHQ CLD7_HUMAN Decreases Expression [54]
Claudin-9 (CLDN9) OTCKI2IZ CLD9_HUMAN Increases Expression [55]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [56]
Calcitonin (CALCA) OTZ11LHB CALC_HUMAN Decreases Methylation [57]
Tyrosine-protein kinase Fyn (FYN) OTLSLVZS FYN_HUMAN Increases Expression [58]
L-lactate dehydrogenase B chain (LDHB) OT9B1CT3 LDHB_HUMAN Increases Expression [59]
Histone H1.0 (H1-0) OTRLJK4Z H10_HUMAN Increases Expression [60]
Interleukin-6 receptor subunit alpha (IL6R) OTCQL07Z IL6RA_HUMAN Affects Expression [51]
Gamma-enolase (ENO2) OTRODL0T ENOG_HUMAN Decreases Expression [61]
Chromogranin-A (CHGA) OTXYX5JH CMGA_HUMAN Decreases Expression [61]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Increases Expression [62]
15-hydroxyprostaglandin dehydrogenase (HPGD) OTYZI6JB PGDH_HUMAN Decreases Methylation [63]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [64]
Methylated-DNA--protein-cysteine methyltransferase (MGMT) OT40A9WH MGMT_HUMAN Increases Expression [65]
Fibulin-1 (FBLN1) OT5MHHOP FBLN1_HUMAN Increases Expression [58]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Increases Expression [66]
G1/S-specific cyclin-D2 (CCND2) OTDULQF9 CCND2_HUMAN Affects Methylation [67]
Cyclin-dependent kinase inhibitor 2A (CDKN2A) OTN0ZWAE CDN2A_HUMAN Decreases Methylation [68]
Killer cell immunoglobulin-like receptor 2DL1 (KIR2DL1) OTL1LBQJ KI2L1_HUMAN Increases Expression [69]
Killer cell immunoglobulin-like receptor 2DL2 (KIR2DL2) OTOVUTJD KI2L2_HUMAN Increases Expression [69]
Killer cell immunoglobulin-like receptor 2DL3 (KIR2DL3) OTFCN53B KI2L3_HUMAN Increases Expression [69]
Killer cell immunoglobulin-like receptor 3DL1 (KIR3DL1) OTPOSXFX KI3L1_HUMAN Increases Expression [69]
Killer cell immunoglobulin-like receptor 2DS4 (KIR2DS4) OT00N6UJ KI2S4_HUMAN Increases Expression [69]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Response To Substance [70]
Tuberin (TSC2) OT47LWI9 TSC2_HUMAN Increases Expression [71]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10) OT4PXBTA TNF10_HUMAN Increases Response To Substance [70]
Homeobox protein Nkx-2.5 (NKX2-5) OTS1SAWM NKX25_HUMAN Increases Expression [72]
Death-associated protein kinase 1 (DAPK1) OTNCNUCO DAPK1_HUMAN Affects Methylation [73]
Claudin-8 (CLDN8) OT7IIWXG CLD8_HUMAN Increases Expression [55]
Small ribosomal subunit protein eS6 (RPS6) OTT4D1LN RS6_HUMAN Decreases Phosphorylation [58]
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform (PPP2CA) OT83PT85 PP2AA_HUMAN Increases Expression [74]
Cyclin-A1 (CCNA1) OTX4HD45 CCNA1_HUMAN Decreases Expression [75]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Decreases Activity [76]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Affects Localization [51]
Tight junction protein ZO-1 (TJP1) OTBDCUPK ZO1_HUMAN Increases Expression [55]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) OT4SO7J4 BNIP3_HUMAN Increases Expression [77]
N-myc-interactor (NMI) OTYVG3NM NMI_HUMAN Increases Expression [58]
NAD(P) transhydrogenase, mitochondrial (NNT) OTAIOGZK NNTM_HUMAN Increases Expression [54]
Cyclin-G2 (CCNG2) OTII38K2 CCNG2_HUMAN Decreases Expression [58]
Occludin (OCLN) OTSUTVWL OCLN_HUMAN Increases Expression [55]
kinase isozyme 4, mitochondrial (PDK4) OTCMHMBZ PDK4_HUMAN Decreases Methylation [78]
Dual specificity protein phosphatase 6 (DUSP6) OT4H6RKW DUS6_HUMAN Increases Expression [58]
Ribonucleoside-diphosphate reductase subunit M2 B (RRM2B) OTE8GBUR RIR2B_HUMAN Increases Expression [79]
Krueppel-like factor 6 (KLF6) OTQY9S7F KLF6_HUMAN Increases Expression [58]
Killer cell immunoglobulin-like receptor 2DL4 (KIR2DL4) OTXN18OA KI2L4_HUMAN Increases Expression [69]
Protein Niban 1 (NIBAN1) OTYOLI12 NIBA1_HUMAN Increases Expression [58]
Calcium homeostasis modulator protein 2 (CALHM2) OTWWM6HI CAHM2_HUMAN Increases Expression [54]
Homeobox protein SIX2 (SIX2) OTYOVGSC SIX2_HUMAN Decreases Expression [54]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 (PLCB1) OT9HYT7A PLCB1_HUMAN Increases Expression [80]
Sal-like protein 4 (SALL4) OTC08PR5 SALL4_HUMAN Affects Methylation [47]
Transcription factor MafB (MAFB) OTH2N3T8 MAFB_HUMAN Increases Expression [54]
Sodium/nucleoside cotransporter 1 (SLC28A1) OTXWVV9O S28A1_HUMAN Increases Response To Substance [81]
------------------------------------------------------------------------------------
⏷ Show the Full List of 202 DOT(s)

References

1 ClinicalTrials.gov (NCT04061239) Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML
2 Daunorubicin FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7063).
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer. 2004 Mar;40(4):536-42.
6 Azacitidine FDA Label
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6796).
8 Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment. Arch Toxicol. 2016 Nov;90(11):2763-2777.
9 Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
10 Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.
11 Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol. 2016 Sep;82(3):683-95. doi: 10.1111/bcp.13008. Epub 2016 Jun 30.
12 Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res. 2007 Jun 1;67(11):5425-33. doi: 10.1158/0008-5472.CAN-06-4431.
13 Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood. 2005 Jun 15;105(12):4752-8. doi: 10.1182/blood-2004-11-4544. Epub 2005 Feb 15.
14 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
15 31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.
16 Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
17 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
18 Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7.
19 Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002 Nov 1;62(21):6172-7.
20 The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro. Physiol Res. 2004;53(6):683-91.
21 Flavonoids as inhibitors of human carbonyl reductase 1. Chem Biol Interact. 2008 Jul 30;174(2):98-108.
22 Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J Pharmacol Exp Ther. 2010 Mar;332(3):755-63.
23 Lack of mechanism-based inactivation of rat hepatic microsomal cytochromes P450 by doxorubicin. Can J Physiol Pharmacol. 1999 Aug;77(8):589-97.
24 Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. Neoplasia. 2009 Dec;11(12):1359-70. doi: 10.1593/neo.91314.
25 Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector in leukemia cells. Int J Nanomedicine. 2010 Aug 9;5:437-44. doi: 10.2147/ijn.s10083.
26 Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 1;68(9):3161-8. doi: 10.1158/0008-5472.CAN-07-6381.
27 Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling. Mutat Res. 2007 Jun 1;619(1-2):16-29. doi: 10.1016/j.mrfmmm.2006.12.007. Epub 2007 Feb 8.
28 Daunorubicin-induced variations in gene transcription: commitment to proliferation arrest, senescence and apoptosis. Biochem J. 2003 Jun 15;372(Pt 3):703-11. doi: 10.1042/BJ20021950.
29 Identification of the key pathway of oxazolinoanthracyclines mechanism of action in cells derived from human solid tumors. Toxicol Appl Pharmacol. 2016 Dec 15;313:159-169. doi: 10.1016/j.taap.2016.10.018. Epub 2016 Oct 22.
30 Daunorubicin attenuates tumor necrosis factor-alpha-induced biosynthesis of plasminogen activator inhibitor-1 in human umbilical vein endothelial cells. Biochim Biophys Acta. 2001 Apr 23;1538(2-3):234-41. doi: 10.1016/s0167-4889(01)00073-8.
31 Anthracyclines trigger apoptosis of both G0-G1 and cycling peripheral blood lymphocytes and induce massive deletion of mature T and B cells. Cancer Res. 2000 Apr 1;60(7):1901-7.
32 CREB/Sp1-mediated MCL1 expression and NFB-mediated ABCB1 expression modulate the cytotoxicity of daunorubicin in chronic myeloid leukemia cells. Toxicol Appl Pharmacol. 2022 Jan 15;435:115847. doi: 10.1016/j.taap.2021.115847. Epub 2021 Dec 25.
33 Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol. 2000;104(4):158-63. doi: 10.1159/000046508.
34 Transcriptional regulation of neutral sphingomyelinase 2 gene expression of a human breast cancer cell line, MCF-7, induced by the anti-cancer drug, daunorubicin. Biochim Biophys Acta. 2009 Nov-Dec;1789(11-12):681-90. doi: 10.1016/j.bbagrm.2009.08.006. Epub 2009 Aug 19.
35 Cotylenin A, a new differentiation inducer, and rapamycin cooperatively inhibit growth of cancer cells through induction of cyclin G2. Cancer Sci. 2008 Aug;99(8):1693-8. doi: 10.1111/j.1349-7006.2008.00867.x.
36 siRNA-mediated down-regulation of iASPP promotes apoptosis induced by etoposide and daunorubicin in leukemia cells expressing wild-type p53. Leuk Res. 2009 Sep;33(9):1243-8. doi: 10.1016/j.leukres.2009.02.016. Epub 2009 Mar 18.
37 Cancer biomarker AKR1B10 and carbonyl metabolism. Chem Biol Interact. 2009 Mar 16;178(1-3):134-7. doi: 10.1016/j.cbi.2008.10.044. Epub 2008 Nov 5.
38 Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett. 2011 Jan 21;585(2):402-8. doi: 10.1016/j.febslet.2010.12.027. Epub 2010 Dec 25.
39 Niemann-Pick C1 protein facilitates the efflux of the anticancer drug daunorubicin from cells according to a novel vesicle-mediated pathway. J Pharmacol Exp Ther. 2006 Jan;316(1):242-7. doi: 10.1124/jpet.105.089482. Epub 2005 Sep 20.
40 Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members. Biochem J. 1999 Oct 15;343 Pt 2(Pt 2):487-504.
41 Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile. Arch Toxicol. 2018 Sep;92(9):2845-2857.
42 Aldo-keto reductase 1C2 fails to metabolize doxorubicin and daunorubicin in vitro. Drug Metab Dispos. 2008 Jun;36(6):991-4. doi: 10.1124/dmd.108.020388. Epub 2008 Mar 5.
43 Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer. 2009 Apr 1;124(7):1727-35. doi: 10.1002/ijc.24108.
44 The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009 Jun;23(6):1019-28.
45 The effect of DNA methylation inhibitor 5-Aza-2'-deoxycytidine on human endometrial stromal cells. Hum Reprod. 2010 Nov;25(11):2859-69.
46 Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma. Eur J Haematol. 2009 Mar;82(3):176-83. doi: 10.1111/j.1600-0609.2008.01189.x. Epub 2008 Dec 5.
47 Novel approach for detecting global epigenetic alterations associated with tumor cell aneuploidy. Int J Cancer. 2007 Oct 1;121(7):1487-93. doi: 10.1002/ijc.22847.
48 The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid l... Leukemia. 2009 Jun;23(6):1019-28.
49 A pilot pharmacokinetic study of oral azacitidine. Leukemia. 2008 Sep;22(9):1680-4.
50 Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs. FEBS Open Bio. 2015 Aug 3;5:634-9.
51 The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. Haematologica. 2008 Jun;93(6):860-9. doi: 10.3324/haematol.12261. Epub 2008 Apr 28.
52 Self-assembled 3D spheroids and hollow-fibre bioreactors improve MSC-derived hepatocyte-like cell maturation in vitro. Arch Toxicol. 2017 Apr;91(4):1815-1832.
53 Clinical significance of the reduced expression of G protein gamma 7 (GNG7) in oesophageal cancer. Br J Cancer. 2008 Jan 29;98(2):410-7. doi: 10.1038/sj.bjc.6604124. Epub 2008 Jan 22.
54 CRISPR-based DNA methylation editing of NNT rescues the cisplatin resistance of lung cancer cells by reducing autophagy. Arch Toxicol. 2023 Feb;97(2):441-456. doi: 10.1007/s00204-022-03404-0. Epub 2022 Nov 6.
55 Prevention of murine experimental corneal trauma by epigenetic events regulating claudin 6 and claudin 9. Jpn J Ophthalmol. 2008 May-Jun;52(3):195-203. doi: 10.1007/s10384-008-0524-z. Epub 2008 Jul 27.
56 Alpha anomer of 5-aza-2'-deoxycytidine down-regulates hTERT mRNA expression in human leukemia HL-60 cells. Biochem Pharmacol. 2008 Feb 15;75(4):965-72. doi: 10.1016/j.bcp.2007.10.018. Epub 2007 Oct 22.
57 Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood. 2009 Mar 19;113(12):2867-8. doi: 10.1182/blood-2008-12-195693.
58 Differential regulation of the p73 cistrome by mammalian target of rapamycin reveals transcriptional programs of mesenchymal differentiation and tumorigenesis. Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):2076-81. doi: 10.1073/pnas.1011936108. Epub 2011 Jan 18.
59 Lactate dehydrogenase-B is silenced by promoter methylation in a high frequency of human breast cancers. PLoS One. 2013;8(2):e57697. doi: 10.1371/journal.pone.0057697. Epub 2013 Feb 21.
60 Characterisation of human histone H1x. Biol Chem. 2005 Jun;386(6):541-51. doi: 10.1515/BC.2005.064.
61 Azacytidine induces cell cycle arrest and suppression of neuroendocrine markers in carcinoids. Int J Clin Exp Med. 2010 Mar 28;3(2):95-102.
62 Promoter methylation as a common mechanism for inactivating E-cadherin in human salivary gland adenoid cystic carcinoma. Cancer. 2007 Jul 1;110(1):87-95. doi: 10.1002/cncr.22758.
63 15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clin Cancer Res. 2009 Jul 15;15(14):4572-80. doi: 10.1158/1078-0432.CCR-08-2518. Epub 2009 Jul 7.
64 DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol. 2008 Jan;28(2):752-71. doi: 10.1128/MCB.01799-07. Epub 2007 Nov 8.
65 CpG methylation-dependent repression of the human O6-methylguanine-DNA methyltransferase gene linked to chromatin structure alteration. Carcinogenesis. 2003 Aug;24(8):1337-45. doi: 10.1093/carcin/bgg086. Epub 2003 May 22.
66 Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target. Cancer Res. 2009 Feb 15;69(4):1527-35. doi: 10.1158/0008-5472.CAN-08-3609. Epub 2009 Feb 3.
67 Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl). 2006 Nov;84(11):911-8. doi: 10.1007/s00109-006-0099-4. Epub 2006 Sep 22.
68 Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. Br J Haematol. 2007 Sep;138(5):616-23. doi: 10.1111/j.1365-2141.2007.06707.x.
69 DNA methylation inhibition increases T cell KIR expression through effects on both promoter methylation and transcription factors. Clin Immunol. 2009 Feb;130(2):213-24. doi: 10.1016/j.clim.2008.08.009. Epub 2008 Oct 22.
70 Sensitization by 5-azacytidine toward death receptor-induced hepatic apoptosis. J Pharmacol Exp Ther. 2009 Jan;328(1):107-15. doi: 10.1124/jpet.108.143560. Epub 2008 Sep 30.
71 Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia. Leuk Res. 2009 Jul;33(7):891-7. doi: 10.1016/j.leukres.2009.01.041. Epub 2009 Feb 27.
72 5-Azacytidine-treated human mesenchymal stem/progenitor cells derived from umbilical cord, cord blood and bone marrow do not generate cardiomyocytes in vitro at high frequencies. Vox Sang. 2008 Aug;95(2):137-48. doi: 10.1111/j.1423-0410.2008.01076.x. Epub 2008 Jun 28.
73 Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma. J Clin Pathol. 2007 Jun;60(6):664-9. doi: 10.1136/jcp.2006.038331.
74 Methylation status of CpG islands flanking a cAMP response element motif on the protein phosphatase 2Ac alpha promoter determines CREB binding and activity. J Immunol. 2009 Feb 1;182(3):1500-8. doi: 10.4049/jimmunol.182.3.1500.
75 Homocysteine inhibits endothelial cell growth via DNA hypomethylation of the cyclin A gene. Blood. 2007 Nov 15;110(10):3648-55. doi: 10.1182/blood-2007-06-096701. Epub 2007 Aug 13.
76 A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
77 Synergism of arsenic trioxide and MG132 in Raji cells attained by targeting BNIP3, autophagy, and mitochondria with low doses of valproic acid and vincristine. Eur J Cancer. 2014 Dec;50(18):3243-61. doi: 10.1016/j.ejca.2014.09.012. Epub 2014 Oct 13.
78 Pyruvate Dehydrogenase Kinase 4 Deficiency Results in Expedited Cellular Proliferation through E2F1-Mediated Increase of Cyclins. Mol Pharmacol. 2017 Mar;91(3):189-196. doi: 10.1124/mol.116.106757. Epub 2016 Dec 21.
79 p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. Cancer Res. 2008 Nov 15;68(22):9358-66. doi: 10.1158/0008-5472.CAN-08-1860.
80 Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16811-6. doi: 10.1073/pnas.0907109106. Epub 2009 Sep 10.
81 Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation. Mol Cancer Ther. 2009 Jan;8(1):225-31. doi: 10.1158/1535-7163.MCT-08-0743.